Abbott Labs and Pfizer are both down this year and beat Q1 estimates, but one is described as a genuine buying opportunity while the other is a potential value trap.
Finnhub07/14, 03:47 AM
- down nearly 23% this year
- 7% yield
- beat Q1 estimates
Figures as quoted by Finnhub
Related assets
Coming up for ABT
Explore next
Latest ABT news
Bloomberg08/21, 04:57 PM
FirstSquawk08/21, 06:28 AM
FirstSquawk08/21, 06:28 AM